Krsnaa Diagnostics Ltd, one of India’s leading integrated diagnostic service providers, has made a strategic investment in Apulki Healthcare Private Limited, the country’s first Public-Private Partnership (PPP) dedicated to cancer and cardiac care hospitals. With this collaboration, Krsnaa will provide a range of advanced diagnostic services at Apulki’s hospitals, aiming to enhance access to specialized diagnostics.
As part of the partnership, Krsnaa Diagnostics will be the exclusive diagnostics partner for Apulki’s state-of-the-art cancer and cardiac hospitals for the next 30+ years. This move cements Krsnaa’s leadership in the growing oncology and cardiac diagnostic sectors. Apulki’s network plans to include over 10 hospitals across India, with the initial launch featuring two advanced 125+ bedded hospitals in Pune and Mumbai, followed by expansions in other metropolitan regions.
This collaboration is aimed at addressing the need for specialized diagnostic services, improving patient outcomes across socioeconomic backgrounds. By offering cutting-edge technologies like MRI, PET CT, Cardiac CT, and Advanced Pathology available around the clock, Krsnaa and Apulki intend to provide seamless diagnostic support for cancer and cardiac care.
Mr. Yash Mutha, Joint Managing Director of Krsnaa Diagnostics Ltd, described this investment as a “game-changer” for Indian healthcare, positioning the company at the forefront of cancer and cardiac care diagnostics. The investment will be funded entirely through internal accruals over the next 2-3 months, ensuring no strain on cash flows. The partnership is also a milestone for Krsnaa’s retail expansion, allowing the company to set up diagnostic centers in premium urban locations.
Ms. Kinjal Babariya, Director of Apulki Healthcare Private Limited, emphasized the significance of integrating diagnostics and treatment under one roof, enhancing patient care, and setting a new benchmark for cancer and cardiac diagnostics in India.
The partnership aims to accelerate early detection, enhance treatment accuracy, and improve survival rates through timely and accurate diagnostics, ultimately advancing healthcare accessibility and quality.
As of 12:50 pm the shares were trading 1.40% higher at ₹849.90 on NSE.
